Business Context and Reporting Period
Company: Adial Pharmaceuticals, Inc. (ADIL)
Filing Type: Form 8-K (Current Report)
Date of Report: February 3, 2026
Reporting Period: Immediate event reporting regarding corporate governance and capital structure changes.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a capital structure adjustment.
Material Changes
- Reverse Stock Split: The Company implemented a 1-for-25 reverse stock split of its Common Stock.
- Share Count Reduction: Outstanding shares reduced from approximately 27.8 million to approximately 1.1 million.
- Effective Date: The split became legally effective at 11:59 p.m. Eastern Time on February 5, 2026.
- Trading Resumption: Stock began trading on a split-adjusted basis on February 6, 2026, under the symbol "ADIL" with a new CUSIP (00688A304).
- Fractional Shares: No fractional shares were issued; holders received cash payments based on the average closing price of the ten days preceding the effective time.
- Equity Adjustments: Proportional adjustments were made to outstanding equity awards and warrants, including exercise prices.
Guidance, Outlook, and Risks
Management Commentary: The primary purpose of the reverse stock split is to raise the per-share trading price to maintain compliance with the Nasdaq Capital Market's minimum bid price requirement of $1.00 per share. The Company also aims to make the bid price more attractive to institutional and retail investors.
Risks and Contingencies: The filing explicitly states there can be no assurance that the reverse stock split will successfully raise the bid price sufficiently or for the required period to maintain listing status.
Investor Verification Checklist
- Verify the new CUSIP number (00688A304) for future trading and record-keeping.
- Confirm the cash payment received for any fractional shares, calculated based on the 10-day average closing price prior to February 5, 2026.
- Monitor the post-split trading price to ensure it meets the $1.00 minimum bid price requirement for continued Nasdaq listing.
- Review adjusted exercise prices and share counts for any held options, warrants, or equity awards.